Clinical trial
Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in…
NCT00435396 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00435396 |
|---|---|
| Title | Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects |
| Official title | A Phase I, Open-label, Vaccination Study to Evaluate the Safety and Immunogenicity of the GSK Biologicals Recombinant CMV gB Sub-unit Vaccine GSK1492903A in CMV-seronegative Healthy Male Adult Subjects |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Infections, Cytomegalovirus |
| Intervention type | Biological |
| Interventions | GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A |
| Enrollment | 40 |
| Start date | Feb 22, 2007 |
| Primary completion | Aug 27, 2008 |
| Completion | Aug 27, 2008 |
| First posted | Feb 15, 2007 |
| Last update posted | May 30, 2017 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: